|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colombo N, Preti E, Landoni F, Carinelli
S, Colombo A, Marini C and Sessa C; ESMO Guidelines Working Group,
: Endometrial cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl
6):vi33–vi38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kounelis S, Kapranos N, Kouri E, Coppola
D, Papadaki H and Jones MW: Immunohistochemical profile of
endometrial adenocarcinoma: A study of 61 cases and review of the
literature. Mod Pathol. 13:379–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Talhouk A, McConechy MK, Leung S, Li-Chang
HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, et al:
A clinically applicable molecular-based classification for
endometrial cancers. Br J Cancer. 113:299–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu T, Wang Y, Jiang R, Lu X and Tian J: A
pathways-based prediction model for classifying breast cancer
subtypes. Oncotarget. 8:58809–58822. 2017.PubMed/NCBI
|
|
6
|
Jahn B, Rochau U, Kurzthaler C, Hubalek M,
Miksad R, Sroczynski G, Paulden M, Bundo M, Stenehjem D, Brixner D,
et al: Personalized treatment of women with early breast cancer: A
risk-group specific cost-effectiveness analysis of adjuvant
chemotherapy accounting for companion prognostic tests OncotypeDX
and Adjuvant!Online. BMC Cancer. 17:6852017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prat A, Pineda E, Adamo B, Galván P,
Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M:
Clinical implications of the intrinsic molecular subtypes of breast
cancer. Breast. 24 (Suppl 2):S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J
and Shi B: Breast cancer intrinsic subtype classification, clinical
use and future trends. Am J Cancer Res. 5:2929–2943.
2015.PubMed/NCBI
|
|
9
|
Oakman C, Viale G and Di Leo A: Management
of triple negative breast cancer. Breast. 19:312–321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trivers KF, Lund MJ, Porter PL, Liff JM,
Flagg EW, Coates RJ and Eley JW: The epidemiology of
triple-negative breast cancer, including race. Cancer Causes
Control. 20:1071–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9 (Suppl 2):S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shabani N, Kuhn C, Kunze S, Schulze S,
Mayr D, Dian D, Gingelmaier A, Schindlback C, Willgeroth F, Sommer
H, et al: Prognostic significance of oestrogen receptor alpha
(ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B
(PR-B) in endometrial carcinomas. Eur J Cancer. 43:2434–2444. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khalifa MA, Mannel RS, Haraway SD, Walker
J and Min KV: Expression of EGFR, HER2/neu, P53, and PCNA in
endometrioid, serous papillary, and clear cell endometrial
adenocarcinomas. Gynecol Oncol. 53:84–92. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samarnthai N, Hall K and Yeh IT: Molecular
profiling of endometrial malignancies. Obstet Gynecol Int.
2010:1623632010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trovik J, Wik E, Werner HM, Krakstad C,
Helland H, Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz
J, Tingulstad S, et al: Hormone receptor loss in endometrial
carcinoma curettage predicts lymph node metastasis and poor outcome
in prospective multicentre trial. Eur J Cancer. 49:3431–3441. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kothari R, Morrison C, Richardson D,
Seward S, O'Malley D, Copeland L, Fowler J and Cohn DE: The
prognostic significance of the triple negative phenotype in
endometrial cancer. Gynecol Oncol. 118:172–175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu N, Wang X and Sheng X: The
clinicopathological characteristics of ‘triple-negative’ epithelial
ovarian cancer. J Clin Pathol. 63:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bulsa M and Urasińska E: Triple negative
endometrial cancer. Ginekol Pol. 88:212–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: PARP-1 expression in breast cancer including
BRCA1-associated, triple negative and basal-like tumors: Possible
implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat.
127:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dedes KJ, Wetterskog D, Mendes-Pereira AM,
Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A,
Lord CJ, et al: PTEN deficiency in endometrioid endometrial
adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl
Med. 2:53ra752010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou C, Bae-Jump VL, Whang YE, Gehrig PA
and Boggess JF: The PTEN tumor suppressor inhibits telomerase
activity in endometrial cancer cells by decreasing hTERT mRNA
levels. Gynecol Oncol. 101:305–310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Łapińska-Szumczyk SM, Supernat AM,
Majewska HI, Gulczyński J, Biernat W, Wydra D and Żaczek AJ:
Immunohistochemical characterisation of molecular subtypes in
endometrial cancer. Int J Clin Exp Med. 8:21981–21990.
2015.PubMed/NCBI
|
|
23
|
Jiang XF, Tang QL, Shen XM, Li HG, Chen
LH, Wang XY, Luo X, Lin ZQ and Jiang GY: Tumor-associated
macrophages, epidermal growth factor receptor correlated with the
triple negative phenotype in endometrial endometrioid
adenocarcinoma. Pathol Res Pract. 208:730–735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwon MJ, Park S, Choi JY, Oh E, Kim YJ,
Park YH, Cho EY, Know MJ, Nam SJ, Im YH, et al: Clinical
significance of CD151 overexpression in subtypes of invasive breast
cancer. Br J Cancer. 106:923–930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41.
2016. View Article : Google Scholar : PubMed/NCBI
|
